DNA and RNA Synthesis Inhibitor Antibiotics

Introduction / Overview

Antibiotics that target nucleic acid synthesis constitute a critical class of antimicrobial agents employed in the management of bacterial infections and, in certain contexts, serve as adjunctive therapy in oncology to control opportunistic infections. The pharmacological activity of these agents is rooted in their capacity to interfere with DNA replication or RNA transcription, thereby compromising bacterial viability. The clinical importance of this class is underscored by the broad spectrum of infections they treat, including urinary tract disease, respiratory tract infection, and tuberculosis, as well as by their utilization in prophylactic regimens for immunocompromised patients. Understanding the pharmacodynamics, pharmacokinetics, therapeutic applications, and safety profiles of DNA and RNA synthesis inhibitors is indispensable for clinicians in optimizing therapeutic outcomes while mitigating adverse events.

Learning objectives:

• Explain the classification of antibiotics that inhibit DNA and RNA synthesis.
• Describe the molecular mechanisms by which these agents disrupt bacterial nucleic acid processes.
• Summarize key pharmacokinetic parameters and dosing considerations.
• Identify approved clinical indications and common off‑label uses.
• Recognize major adverse effects, drug interactions, and special population considerations.

Classification

Chemical Families

Antibiotics inhibiting nucleic acid synthesis are grouped primarily into three chemical families, each characterized by distinct structural motifs and target enzymes:

• Fluoroquinolones – 4‑quinolone core with a fluorine atom at position 6, various substitutions at positions 1, 7, and 8.
• Rifamycins – macrocyclic lactam ring with a piperazine substituent and a 4‑hydroxy‑5‑alkyl group.
• Nitroimidazoles – imidazole ring bearing a nitro group at position 1 and variable alkyl side chains.

Mechanistic Subclassification

Within each chemical family, agents can be further subdivided based on the specific bacterial enzyme or process they impair:

• DNA gyrase and topoisomerase IV inhibitors – fluoroquinolones.
• RNA polymerase inhibitors – rifamycins.
• DNA damage via free radical formation – nitroimidazoles.

Mechanism of Action

DNA Gyrase and Topoisomerase IV Inhibition (Fluoroquinolones)

Fluoroquinolones exert bactericidal activity by binding to the DNA–enzyme complex formed during the normal catalytic cycle of bacterial gyrase (DNA gyrase) and topoisomerase IV. The interaction stabilizes the transient double‑strand break induced by the enzyme, thereby preventing re‑ligation of the DNA strands. The resultant accumulation of double‑strand breaks leads to irreversible DNA fragmentation and cell death. The inhibitory potency is modulated by the presence of a methoxy group at position 7 and a piperazine ring at position 8, which enhance penetration into Gram‑negative bacteria.

RNA Polymerase Inhibition (Rifamycins)

Rifamycins bind to the β‑subunit of bacterial RNA polymerase, specifically occupying the rifampin binding site adjacent to the active center. This prevents the initiation of RNA chain elongation by blocking the entrance of the nascent RNA transcript. The inhibition is most effective against actively replicating bacteria. The binding affinity exhibits a pH dependence, with maximal activity at physiological pH values.

DNA Damage via Free Radical Formation (Nitroimidazoles)

Upon entering anaerobic bacterial cells, nitroimidazoles undergo reductive activation by nitroreductases, generating nitro anion radicals. These radicals interact with bacterial DNA, causing strand breaks and base modifications that compromise replication fidelity. The antimicrobial effect is selective for anaerobes due to the requirement of low oxygen tension for radical formation. The free radical mechanism also renders nitroimidazoles active against certain protozoal parasites.

Pharmacokinetics

Absorption

• Fluoroquinolones – Oral bioavailability ranges from 70% to 80% for ciprofloxacin and levofloxacin; higher for moxifloxacin (≈90%). Food can reduce absorption by up to 30% for some agents.
• Rifampin – Oral bioavailability around 60%; absorption is enhanced by gastric acid; co‑administration with antacids decreases C_max.
• Metronidazole – Oral bioavailability near 100%; rapid absorption with peak plasma concentrations within 30–90 minutes.

Distribution

• Fluoroquinolones – Extensive tissue penetration; high protein binding (≥80%); large volume of distribution (≈1.5–3 L/kg). Cerebrospinal fluid penetration varies: 25–35% of plasma concentrations for ciprofloxacin.
• Rifampin – High protein binding (≈80%); volume of distribution ≈10 L. Penetrates well into bone, synovial fluid, and the central nervous system.
• Metronidazole – Moderate protein binding (≈30%); volume of distribution ≈0.6–0.9 L/kg; penetrates into the CNS and ocular fluids.

Metabolism

• Fluoroquinolones – Minimal hepatic metabolism; excreted unchanged via kidneys (≈30–60% of dose). Enzyme-mediated metabolism (CYP3A4) is negligible for most agents.
• Rifampin – Induces hepatic CYP450 enzymes, especially CYP3A4; metabolized by glucuronidation and sulfation; active metabolites contribute to efficacy.
• Metronidazole – Metabolized by hepatic microsomal enzymes (CYP2A6, CYP3A4) to inactive metabolites; elimination primarily via urine.

Excretion

• Fluoroquinolones – Renal clearance dominates; dose adjustment required for creatinine clearance <30 mL/min.
• Rifampin – Renal excretion accounts for ≈40% of clearance; hepatic metabolism remains significant.
• Metronidazole – Renal excretion of unchanged drug is about 70%; metabolite excretion via urine.

Half‑Life and Dosing Considerations

The elimination half‑life (t_1/2) ranges from 4 to 6 hours for fluoroquinolones, approximately 8–10 hours for rifampin, and 8 hours for metronidazole. The typical dosing interval aligns with the half‑life to maintain therapeutic concentrations above the minimum inhibitory concentration (MIC) for the target organism. For fluoroquinolones, the dosing schedule may be every 12 hours; rifampin is often dosed once daily; metronidazole may require twice-daily administration.

Generic pharmacokinetic equation: C(t) = C₀ × e⁻ᵏᵗ, where k = ln(2) / t_1/2. The area under the concentration–time curve (AUC) is approximated by AUC = Dose / Clearance.

Therapeutic Uses / Clinical Applications

Approved Indications

• Fluoroquinolones – Urinary tract infections, community‑acquired pneumonia, acute bacterial prostatitis, skin and soft tissue infections, intra‑abdominal infections, and multidrug‑resistant gram‑negative bacilli such as Pseudomonas aeruginosa (levofloxacin).
• Rifampin – Primary agent for Mycobacterium tuberculosis treatment in combination regimens; prophylaxis for latent tuberculosis infection; treatment of leprosy and certain opportunistic infections (e.g., invasive aspergillosis when combined with amphotericin).
• Metronidazole – Bacterial vaginosis, trichomoniasis, anaerobic bacterial infections (e.g., intra‑abdominal, pelvic), and protozoal infections such as amoebiasis and giardiasis.

Off‑Label Uses

• Fluoroquinolones are sometimes employed in the treatment of complicated skin infections and as empiric therapy for febrile neutropenia, despite recommendations to reserve them for specific indications.
• Rifampin has been used adjunctively in the management of osteomyelitis caused by gram‑positive organisms and in the treatment of certain fungal infections when combined with azoles.
• Metronidazole is occasionally prescribed for dental abscesses and chronic periodontitis due to its activity against anaerobes.

Adverse Effects

Common Side Effects

• Fluoroquinolones – Gastrointestinal upset (nausea, diarrhea), dizziness, headache, phototoxicity, and mild rash. Tendinopathy may manifest as pain or swelling of the Achilles tendon.
• Rifampin – Hepatotoxicity manifested by elevated transaminases, orange discoloration of bodily fluids, and gastrointestinal disturbances.
• Metronidazole – Metallic taste, nausea, abdominal discomfort, and a disulfiram‑like reaction when alcohol is consumed.

Serious / Rare Adverse Reactions

• Fluoroquinolones – QT interval prolongation leading to torsades de pointes; central nervous system effects including seizures and psychosis; irreversible peripheral neuropathy; aortic aneurysm or dissection risk in susceptible individuals.
• Rifampin – Severe hepatotoxicity (cholestatic jaundice), hypersensitivity reactions (rash, fever, eosinophilia), drug-induced lupus, and autoimmune hemolytic anemia.
• Metronidazole – Neurotoxicity presenting as ataxia, peripheral neuropathy, and paresthesias, especially with prolonged high‑dose therapy.

Black Box Warnings

• Fluoroquinolones – Warned for the risk of severe tendinopathy, tendon rupture, and irreversible peripheral neuropathy. Caution is advised in patients with a history of tendon disorders or concurrent use of systemic glucocorticoids.
• Rifampin – Associated with hepatotoxicity; routine monitoring of liver function tests is required. No black box warning exists, but vigilance is necessary.
• Metronidazole – No black box warning, yet prolonged use may lead to neurotoxicity; careful dosing is advised.

Drug Interactions

Major Drug‑Drug Interactions

• Fluoroquinolones – Reduced absorption when co‑administered with calcium, magnesium, aluminum, or iron salts; increased plasma concentrations of drugs metabolized by CYP1A2 (e.g., theophylline) due to inhibition of the enzyme; potential for increased risk of QT prolongation when combined with other QT‑extending agents.
• Rifampin – Strong inducer of CYP3A4, CYP2C9, and CYP2C19; concomitant use with statins, oral contraceptives, anticoagulants (warfarin), and antiretrovirals can reduce therapeutic levels. Rifampin also induces P‑gp, affecting the pharmacokinetics of drugs such as digoxin.
• Metronidazole – Inhibits CYP2E1, leading to elevated plasma levels of ethanol; may potentiate the effects of other drugs metabolized via CYP2E1. Interaction with warfarin can increase INR levels.

Contraindications

• Fluoroquinolones – Contraindicated in patients with a history of myasthenia gravis or those receiving concurrent medications that may precipitate seizures.
• Rifampin – Contraindicated in patients with severe liver disease or hypersensitivity to rifampin or other macrolides.
• Metronidazole – Contraindicated in patients with a history of severe liver disease or in those with a disulfiram reaction.

Special Considerations

Pregnancy / Lactation

• Fluoroquinolones – Category C; animal studies have shown skeletal fluorosis in offspring. Avoid in pregnancy unless no alternatives exist.
• Rifampin – Category C; reduces efficacy of oral contraceptives and is associated with hepatotoxicity. Use with caution during pregnancy; avoid lactation due to high excretion in milk.
• Metronidazole – Category B; generally considered safe in pregnancy, but caution advised in the first trimester. Excreted in breast milk; short‑term use is acceptable.

Pediatric / Geriatric Considerations

• In children, fluoroquinolones are generally reserved for serious infections due to concerns about cartilage damage. Age‑based dosing adjustments are required based on renal function.
• In geriatric patients, reduced renal clearance necessitates dose reduction for fluoroquinolones and rifampin; monitoring for CNS side effects is essential.

Renal / Hepatic Impairment

• Fluoroquinolones – Dose adjustment based on creatinine clearance; avoid in severe renal impairment for agents with high renal excretion.
• Rifampin – Dose may be reduced or held in severe hepatic dysfunction; careful monitoring of liver enzymes is mandatory.
• Metronidazole – Metabolized hepatically; dose adjustment not routinely required for mild hepatic impairment but caution in severe disease.

Summary / Key Points

• DNA and RNA synthesis inhibitors are pivotal antibiotics that target bacterial enzymes essential for nucleic acid processing.
• Fluoroquinolones inhibit DNA gyrase/topoisomerase IV; rifampin blocks RNA polymerase; nitroimidazoles generate DNA‑damaging radicals.
• Pharmacokinetic profiles influence dosing intervals: fluoroquinolones (t_1/2 4–6 h), rifampin (t_1/2 8–10 h), metronidazole (t_1/2 8 h).
• Major adverse effects include tendinopathy and neurotoxicity for fluoroquinolones, hepatotoxicity for rifampin, and neurotoxicity for metronidazole.
• Drug interactions arise from enzyme induction (rifampin) and inhibition (fluoroquinolones), necessitating vigilant monitoring.
• Special populations require dose adjustments and careful monitoring of organ function and concomitant medications.

References

1. Gilbert DN, Chambers HF, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 53rd ed. Sperryville, VA: Antimicrobial Therapy Inc; 2023.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.